{"transactions":[{"id":888502,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-2 Preferred Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":6135,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6135},"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888501,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":false,"shares":13029,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":13029},"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888500,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":6135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date."}],"balance_after":30275,"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}},{"id":888499,"issuer":{"id":8097,"kind":"organization","name":"20/20 Biolabs, Inc."},"owners":[{"id":65219,"kind":"person","name":"Rollins John Woodson","position":1,"cik":"0002112941","reported_name":"Rollins John Woodson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-24T00:09:32.000Z","date":"2026-02-19","kind":"exercise","planned":false,"acquired":true,"shares":13029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 19, 2026, all shares of series A preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A preferred stock had no expiration date."}],"balance_after":24140,"source":{"system":"sec-edgar","filing":"0001213900-26-019456","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026019456/ownership.xml","form_type":"4"}}]}